Industry
Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and Company
Total Trials
3
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
Failure Rate
0.0%
0 terminated/withdrawn out of 3 trials
Success Rate
100.0%
+13.5% vs industry average
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Phase 1
3(100.0%)
3Total
Phase 1(3)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (3)
Showing 3 of 3 trials
NCT07247357Phase 1Completed
A Study of LY4064809 in Healthy Adult Chinese Participants
Role: collaborator
NCT06991179Phase 1Completed
A Study of Food Effect and Esomeprazole on LY4064809 in Healthy Adult Participants
Role: lead
NCT06901336Phase 1Completed
A Study of LY4064809 [14C]-STX-478 in Healthy Male Participants
Role: lead
All 3 trials loaded